Top Page
Sino Biopharmaceutical
(OTC:1177)
Sino Biopharmaceutical (1177) vs. iShares MSCI Hong Kong ETF (EWH)
Sino Biopharmaceutical Business Overview & Revenue Model
Sino Biopharmaceutical Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 28.87B | 26.20B | 28.78B | 26.86B | 23.65B |
| Gross Profit | 23.53B | 21.21B | 22.98B | 21.53B | 18.46B |
| EBITDA | 6.11B | 6.98B | 6.69B | 19.87B | 6.54B |
| Net Income | 3.50B | 2.33B | 5.00B | 14.61B | 4.34B |
Balance Sheet | |||||
| Total Assets | 65.41B | 63.60B | 64.06B | 60.54B | 47.21B |
| Cash, Cash Equivalents and Short-Term Investments | 14.60B | 14.12B | 16.92B | 15.79B | 16.43B |
| Total Debt | 9.78B | 12.58B | 13.98B | 12.12B | 14.21B |
| Total Liabilities | 22.63B | 25.43B | 26.12B | 22.81B | 24.79B |
| Stockholders Equity | 31.96B | 30.47B | 29.75B | 30.29B | 16.75B |
Cash Flow | |||||
| Free Cash Flow | 5.22B | 4.36B | 4.56B | 3.47B | 3.47B |
| Operating Cash Flow | 6.62B | 6.07B | 6.27B | 5.37B | 5.33B |
| Investing Cash Flow | -1.71B | -756.98M | -4.07B | -2.52B | -7.85B |
| Financing Cash Flow | -6.32B | -6.55B | -3.19B | -3.23B | 2.23B |
Sino Biopharmaceutical Technical Analysis
Sino Biopharmaceutical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | HK$54.45B | 24.27 | 14.19% | 1.14% | 14.36% | 33.22% | |
74 Outperform | $102.33B | 28.37 | 8.17% | ― | 7.52% | -1.92% | |
69 Neutral | $94.79B | 49.95 | 6.14% | 11.85% | 7.63% | -24.23% | |
61 Neutral | $127.75B | ― | -0.72% | ― | 49.33% | 90.96% | |
60 Neutral | HK$15.14B | 5.55 | -7.43% | 4.78% | 11.72% | -20.69% | |
55 Neutral | HK$83.03B | ― | -8.98% | ― | -54.66% | -123.11% | |
51 Neutral | HK$33.78B | ― | -19.78% | ― | 25.96% | 39.58% |
Sino Biopharmaceutical Corporate Events
Sino Biopharmaceutical Limited announced that its jointly developed drug, LM-108, a CCR8 monoclonal antibody, has been included in China’s Breakthrough Therapy Designation process for treating advanced gastric/gastroesophageal junction adenocarcinoma. The drug has shown promising results in clinical trials, demonstrating significant efficacy in overcoming resistance to PD-1/PD-L1 inhibitors and offering new treatment options for patients who have failed previous therapies. LM-108 is the most advanced CCR8 monoclonal antibody globally and is expected to become a next-generation immunotherapy for various tumors, potentially impacting the company’s market positioning and providing new hope for patients.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced promising results from preclinical and Phase Ib clinical studies of rovadicitinib, a novel treatment for acute graft-versus-host disease (aGVHD), presented at the 2025 European Hematology Association Congress. The drug, a dual JAK/ROCK pathway inhibitor, showed an overall response rate of 84.6% at 28 days and a 12-month survival rate of 92.3%. These findings suggest rovadicitinib as a potential alternative for patients with steroid-refractory aGVHD, highlighting its rapid and sustained response and the ability to reduce steroid use. The company has also initiated a Phase III trial for chronic GVHD, reinforcing its commitment to advancing treatment options in this field.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced that its self-developed Class 1 innovative drug, TDI01 suspension, has been included in the Breakthrough Therapy Designation process by China’s Center for Drug Evaluation. TDI01, a ROCK2 inhibitor, has shown significant efficacy and safety in treating moderate to severe chronic graft-versus-host disease (cGVHD) and is also being trialed for other conditions like idiopathic pulmonary fibrosis. This advancement underscores the company’s commitment to providing innovative treatment options and may enhance its position in the pharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced significant progress in its innovation-driven development strategy, with a notable increase in revenue from innovative products and plans to launch several new products annually. The company is advancing multiple promising R&D pipelines, including drugs for chronic obstructive pulmonary disease, various cancers, and metabolic dysfunction-associated steatohepatitis, positioning itself as a leader in the biopharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited held its Annual General Meeting on June 10, 2025, where all proposed resolutions were approved by shareholders. Key resolutions included the adoption of the company’s financial statements for 2024, approval of a final dividend, re-election of directors, and authorization of the board to manage share capital and remuneration. The approval of these resolutions reflects strong shareholder support and positions the company for continued growth and stability in the biopharmaceutical sector.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has received approval from the Center for Drug Evaluation of China to initiate a Phase III clinical study for its innovative drug, TQB2868 injection, aimed at treating metastatic pancreatic ductal adenocarcinoma (mPDAC). This drug, combined with anlotinib hydrochloride capsules and chemotherapy, has shown promising results in early trials, potentially becoming a groundbreaking first-line treatment option for pancreatic cancer, which currently has limited effective treatments and a low survival rate.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has announced that its innovative drug, TQC3721 inhalation suspension, has received approval from China’s National Medical Products Administration to commence a phase III clinical study for COPD treatment. This drug, a PDE3/4 inhibitor, offers both bronchodilatory and anti-inflammatory effects, potentially improving treatment outcomes for COPD patients. The approval marks a significant step in the company’s research and development efforts, positioning it as a leader in COPD treatment innovation. The study will evaluate the drug’s efficacy and safety across a broader patient base, which could enhance its market positioning and provide a competitive edge in the global pharmaceutical industry.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has announced the results of its phase III clinical study for benmelstobart injection, with or without anlotinib, as a maintenance treatment for non-small cell lung cancer (NSCLC) at the 2025 ASCO Annual Meeting. The study demonstrated a significant extension in median progression-free survival for patients receiving the combination treatment, marking a potential shift in clinical practice guidelines and offering new hope for NSCLC patients. The study’s findings have led to the acceptance of a marketing application for the new indication by the National Medical Products Administration of China, highlighting the potential impact on the company’s operations and industry positioning.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$5.10 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced the successful results of their phase III clinical study at the 2025 ASCO Annual Meeting, showcasing the efficacy of benmelstobart injection combined with anlotinib hydrochloride capsules as a first-line treatment for PD-L1 positive advanced non-small cell lung cancer (NSCLC). The study, known as CAMPASS, demonstrated a significant improvement in progression-free survival (PFS) compared to pembrolizumab, with a notable 6.1-month prolongation in median PFS and a 40% reduction in the risk of disease progression or death in patients with TPS ≥50%. This advancement is expected to enhance first-line treatment options for PD-L1 positive advanced NSCLC patients in China, marking a significant clinical value in the oncology field.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced promising preliminary results from a Phase II clinical study of its bi-functional fusion protein, TQB2868, combined with anlotinib and chemotherapy for treating metastatic pancreatic ductal adenocarcinoma (mPDAC). The study, presented at the 2025 ASCO Annual Meeting, showed significant improvements in objective remission and disease control rates compared to traditional chemotherapy regimens, with a favorable safety profile. This development could mark a significant breakthrough in pancreatic cancer treatment, potentially positioning TQB2868 as the first immune checkpoint inhibitor for first-line treatment, thereby improving patient survival and quality of life.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited has announced promising preliminary data from its phase I clinical study of TQB2102, a novel bispecific anti-HER2 antibody-drug conjugate, presented at the 2025 ASCO Annual Meeting. The study showed significant efficacy in treating various HER2-related cancers, including breast, colorectal, and gastric cancers, with a favorable safety profile compared to existing treatments. The ongoing phase III trials of TQB2102 are expected to potentially transform the treatment landscape for HER2 ADCs, offering a new therapeutic option with a lower incidence of adverse effects.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$7.00 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical has announced positive results from its Phase III clinical study of Benmelstobart Injection combined with chemotherapy and Anlotinib for treating advanced squamous non-small cell lung cancer (sq-NSCLC). The study, presented at the 2025 ASCO Annual Meeting, showed a significant improvement in median progression-free survival and overall response rates compared to the control group. This breakthrough could potentially change the treatment landscape for sq-NSCLC, offering new hope for patients with limited options.
The most recent analyst rating on (HK:1177) stock is a Buy with a HK$4.80 price target. To see the full list of analyst forecasts on Sino Biopharmaceutical stock, see the HK:1177 Stock Forecast page.
Sino Biopharmaceutical Limited announced the details of its upcoming annual general meeting scheduled for June 10, 2025. Key agenda items include the adoption of financial statements for 2024, approval of a final dividend, re-election of several directors, and the re-appointment of Ernst & Young as auditors. The meeting will also consider resolutions to authorize the board to issue additional shares, potentially impacting the company’s capital structure and shareholder value.
Sino Biopharmaceutical Limited announced that its co-developed drug, penpulimab injection, has received approval from the US FDA for marketing. This approval marks a significant milestone as penpulimab is the only novel PD-1 monoclonal antibody with IgG1 subtype and Fc engineering, enhancing efficacy while minimizing adverse reactions. The drug is indicated for the treatment of recurrent or metastatic non-keratinizing nasopharyngeal carcinoma (NPC) and has several approved indications in China. The company plans to further develop penpulimab’s indications and expand into international markets to address urgent clinical needs globally.
Sino Biopharmaceutical Limited announced that it will present 45 research results at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, including 12 oral sessions and 4 Late-Breaking Abstracts. This participation highlights the company’s ongoing commitment to advancing cancer treatment, potentially enhancing its industry standing and offering significant insights for stakeholders involved in oncology research and development.
Sino Biopharmaceutical Limited’s board of directors has proposed the adoption of amended and restated articles of association to align with recent changes in the Hong Kong Stock Exchange’s Listing Rules, including the expansion of the paperless listing regime and the treasury shares regime. The proposed amendments aim to enhance clarity and make consequential changes, pending shareholder approval at the upcoming annual general meeting.
Sino Biopharmaceutical Limited announced that its self-developed drug, TQB3019 (BTK PROTAC), has been approved for clinical trials by China’s National Medical Products Administration. This drug targets hematologic tumors and represents a significant advancement in overcoming BTK inhibitor resistance, with promising preclinical results showing efficacy and safety. The company is also progressing with other related drug developments, aiming to address unmet clinical needs globally.
Sino Biopharmaceutical Limited announced that its application for a clinical trial of TQB6411, an EGFR/c-Met bispecific ADC, has been accepted by China’s Center for Drug Evaluation. TQB6411 is designed to target lung cancer driver genes, offering a potential treatment by blocking key signaling pathways and inducing cell death. The company has completed extensive pharmacological and safety verifications, showing promising results in vitro and in vivo. Alongside TQB6411, Sino Biopharmaceutical is also developing other drugs targeting EGFR and c-Met, highlighting its commitment to providing better treatment options for cancer patients worldwide.
Sino Biopharmaceutical Limited has received approval from the National Medical Products Administration of China to conduct a Phase I clinical trial for its self-developed drug TQB2101, intended for treating advanced malignant tumors. This approval marks a significant step in the company’s expansion of its ADC portfolio, which now includes four drugs in clinical stages. The trial will assess the safety and efficacy of TQB2101, which has shown promising preclinical results in targeting ROR1-positive tumors. This development is part of the company’s broader strategy to leverage its ADC technology platform to innovate and contribute to global health.